{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:44:18Z","timestamp":1773398658634,"version":"3.50.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.34627","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T16:45:49Z","timestamp":1637081149000},"page":"e2134627","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis"],"prefix":"10.1001","volume":"4","author":[{"given":"Jue","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianrun","family":"Cai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Dahal","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Weiner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"issue":"6","key":"zoi210978r1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/joim.v289.6","article-title":"Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.","volume":"289","author":"Piehl","year":"2021","journal-title":"J Intern Med"},{"issue":"12","key":"zoi210978r2","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review.","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"issue":"18","key":"zoi210978r3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1212\/WNL.0000000000008319","article-title":"Head-to-head drug comparisons in multiple sclerosis: urgent action needed.","volume":"93","author":"Tur","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"zoi210978r4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/03007995.2016.1248380","article-title":"Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.","volume":"33","author":"Fox","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"zoi210978r5","article-title":"Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.","volume":"3","author":"Hersh","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"zoi210978r6","article-title":"Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience.","volume":"3","author":"Vollmer","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"zoi210978r7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1212\/CPJ.0000000000000487","article-title":"Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.","volume":"8","author":"Vollmer","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"zoi210978r8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"zoi210978r9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.","volume":"90","author":"Kalincik","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"zoi210978r10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.","volume":"24","author":"Lorscheider","year":"2018","journal-title":"Mult Scler"},{"issue":"2","key":"zoi210978r11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/acn3.2019.6.issue-2","article-title":"Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.","volume":"6","author":"Vollmer","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"zoi210978r12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.msard.2019.05.026","article-title":"The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis: an Italian multicentre study.","volume":"33","author":"Curti","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"zoi210978r13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s13311-019-00781-w","article-title":"Effects of natalizumab and fingolimod on clinical, cognitive, and magnetic resonance imaging measures in multiple sclerosis.","volume":"17","author":"Preziosa","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"10","key":"zoi210978r14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038861","article-title":"Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.","volume":"10","author":"Butzkueven","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"zoi210978r15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000505778","article-title":"Effectiveness of fingolimod versus natalizumab as second-line therapy for relapsing-remitting multiple sclerosis in Spain: second-line GATE study.","volume":"83","author":"Meca-Lallana","year":"2020","journal-title":"Eur Neurol"},{"issue":"6","key":"zoi210978r16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"zoi210978r17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/03007995.2020.1739009","article-title":"Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.","volume":"36","author":"Siddiqui","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"zoi210978r18","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/acn3.v7.9","article-title":"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"zoi210978r19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis.","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"zoi210978r20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/ene.2019.26.issue-8","article-title":"Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.","volume":"26","author":"Boremalm","year":"2019","journal-title":"Eur J Neurol"},{"issue":"8","key":"zoi210978r21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.autrev.2006.02.012","article-title":"A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study.","volume":"5","author":"Gauthier","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"2","key":"zoi210978r22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"zoi210978r23","doi-asserted-by":"publisher","first-page":"h1885","DOI":"10.1136\/bmj.h1885","article-title":"Development of phenotype algorithms using electronic medical records and incorporating natural language processing.","volume":"350","author":"Liao","year":"2015","journal-title":"BMJ"},{"issue":"12","key":"zoi210978r24","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1038\/s41596-019-0227-6","article-title":"High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP).","volume":"14","author":"Zhang","year":"2019","journal-title":"Nat Protoc"},{"issue":"11","key":"zoi210978r25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078927","article-title":"Modeling disease severity in multiple sclerosis using electronic health records.","volume":"8","author":"Xia","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"zoi210978r26","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000864","article-title":"Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity.","volume":"7","author":"Zhang","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"zoi210978r27","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"zoi210978r28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/acn3.v8.4","article-title":"Leveraging electronic health records data to predict multiple sclerosis disease activity.","volume":"8","author":"Ahuja","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"zoi210978r29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years.","volume":"18","author":"Nelson","year":"2011","journal-title":"J Am Med Inform Assoc"},{"key":"zoi210978r30","journal-title":"Neurology"},{"issue":"5","key":"zoi210978r31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/jamia.2009.001560","article-title":"Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications.","volume":"17","author":"Savova","year":"2010","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"zoi210978r33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","year":"1983","journal-title":"Biometrika"},{"key":"zoi210978r34","doi-asserted-by":"publisher","first-page":"f6409","DOI":"10.1136\/bmj.f6409","article-title":"Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research.","volume":"347","author":"Freemantle","year":"2013","journal-title":"BMJ"},{"key":"zoi210978r35","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"zoi210978r36","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jama.2019.21558","article-title":"Using propensity score methods to create target populations in observational clinical research.","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"zoi210978r37","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1541-0420.2005.00377.x","article-title":"Doubly robust estimation in missing data and causal inference models.","volume":"61","author":"Bang","year":"2005","journal-title":"Biometrics"},{"issue":"427","key":"zoi210978r38","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/01621459.1994.10476818","article-title":"Estimation of regression coefficients when some regressors are not always observed.","volume":"89","author":"Robins","year":"2012","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"zoi210978r39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/biom.v75.1","article-title":"On doubly robust estimation of the hazard difference.","volume":"75","author":"Dukes","year":"2019","journal-title":"Biometrics"},{"issue":"476","key":"zoi210978r41","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1198\/016214506000000735","article-title":"The adaptive lasso and its oracle properties.","volume":"101","author":"Zou","year":"2012","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"zoi210978r42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/EDE.0000000000000457","article-title":"Sensitivity analysis without assumptions.","volume":"27","author":"Ding","year":"2016","journal-title":"Epidemiology"},{"issue":"5","key":"zoi210978r43","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"4","key":"zoi210978r44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi210978r45","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2018.21554","article-title":"Using the E-value to assess the potential effect of unmeasured confounding in observational studies.","volume":"321","author":"Haneuse","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"zoi210978r48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1214\/14-STS493","article-title":"Structural nested models and G-estimation: the partially realized promise.","volume":"29","author":"Vansteelandt","year":"2014","journal-title":"Stat Sci"},{"key":"zoi210978r32","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"},{"key":"zoi210978r40","unstructured":"Hou? J, Bradic? J, Xu? R. Estimating treatment effect under additive hazards models with high-dimensional covariates. arXiv. Preprint posted online June 29, 2019."},{"key":"zoi210978r46","unstructured":"R Foundation. R: a language and environment for statistical computing. R Project for Statistical Computing; 2020. Accessed April 5, 2021. https:\/\/www.R-project.org\/"},{"key":"zoi210978r47","unstructured":"GitHub. hjmarquis \/ MS_EHR_paper3. Accessed October 6, 2021. https:\/\/github.com\/hjmarquis\/MS_EHR_paper3"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2786182\/hou_2021_oi_210978_1636390122.14323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T16:45:59Z","timestamp":1637081159000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2786182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.34627","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]}}}